RPG Life Sciences Valuation Multiples

RPG Life Sciences Overview

About RPG Life Sciences

RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.

Founded

2007

HQ

Employees

1.8K

Website

rpglifesciences.com

Financials (FY)

Revenue: $74M

EBITDA: $19M

EV

$453M

Valuation Multiples

Start free trial

RPG Life Sciences Financials

RPG Life Sciences reported last fiscal year revenue of $74M and EBITDA of $19M.

In the same fiscal year, RPG Life Sciences generated $46M in gross profit, $19M in EBITDA, and $12M in net income.

RPG Life Sciences P&L

In the most recent fiscal year, RPG Life Sciences reported revenue of $74M and EBITDA of $19M.

RPG Life Sciences is profitable as of last fiscal year, with gross margin of 63%, EBITDA margin of 25%, and net margin of 16%.

RPG Life Sciences Stock Performance

RPG Life Sciences has current market cap of $480M, and enterprise value of $453M.

RPG Life Sciences' stock price is $29.02.

RPG Life Sciences has an EPS (earnings per share) of $0.73.

RPG Life Sciences Valuation Multiples

RPG Life Sciences trades at 6.2x EV/Revenue multiple, and 24.5x EV/EBITDA.

RPG Life Sciences Financial Valuation Multiples

As of August 3, 2026, RPG Life Sciences has market cap of $480M and EV of $453M.

RPG Life Sciences has a P/E ratio of 39.8x.

RPG Life Sciences Margins & Growth Rates

In the most recent fiscal year, RPG Life Sciences reported gross margin of 63%, EBITDA margin of 25%, and net margin of 16%.

RPG Life Sciences Operational KPIs

RPG Life Sciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.

RPG Life Sciences' Rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

RPG Life Sciences' Rule of X is 30% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Acquisitions by RPG Life Sciences

RPG Life Sciences has acquired 1 company to date.

Last acquisition by RPG Life Sciences was on July 28th 2026. RPG Life Sciences acquired Actis Generics for $8M (EV/Revenue multiple available to Pro users).